Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Next Generation Sequencing Market Worth US$30,424.3 Million by 2031: Visiongain Reports Ltd

In This Article:

Visiongain Reports Ltd
Visiongain Reports Ltd

Visiongain has published a new report entitled the Next Generation Sequencing Market 2021-2031. It includes profiles of Next Generation Sequencing Market By Technology (SBS, Ion Semiconductor Sequencing, Single Real Time Sequencing, Nanopore Sequencing & Other Sequencing Technology), By Products & Services (Instruments, Reagents & Consumables and Services), By Sequencing Tools (Illumina, Thermo Fischer, Oxford Nanopore, Pacific Biosciences and other platforms), By Reagents & Consumables, By Services (Sequencing Services & Bioinformatics), By Sequencing Services ( Whole Genome Sequencing, Targeted Re-Sequencing, Exome Sequencing, RNA Sequencing, ChIP sequencing, De Novo Sequencing, Methyl Sequencing and Others) By Applied Research ( Drug Discovery, Diagnostics, Personalized Medicine, Genetic Screening, Infectious Diseases, Agriculture & Animal Research & Others) By End Users (Biotech firms, Pharmaceutical companies, Hospital & Diagnostics centers and Others), By Leading National Market Analysis Plus Analysis of Leading NGS Market Players and COVID Recovery Scenarios.

Visiongain’s lead analyst says: ‘The Global Next Generation Sequencing Market was valued to be at US$ 9,368.3 million in 2021 and is expected to reach US$ 30,424.3 million by 2031 at a CAGR of 12.5% from 2021 – 2031. Rising preference for personalised medicine in developed as well as developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase NGS market concentration over the forecast period’.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/ngs-market-2021/#download_sampe_div

How has COVID-19 had a positive impact on the Next Generation Sequencing Market?

The primary application of NGS for infectious diseases has been useful to detect the virus without prior knowledge of the infectious agent. NGS workflows were deployed in various research labs and pathological laboratories to detect the SARS-CoV-2 virus. The NGS platforms and workflows are being used for surveillance, detection, tracking multiple variants and epidemiological studies. Various sequencing service providers introduced new RNA sequencing kits to support various studies that are being conducted with coronavirus-related which includes library preparation for whole genome sequencing, shot gun sequencing and targeted sequencing. For instance, Perkin Elmer introduced NEXTFLEX Rapid XP DNA-Seq kit which has been suitable for sequencing human DNA to analyse the clinical outcome in COVID-19. In March 2021, ThermoFischer introduced Ion AmpliSeq SARS-CoV-2 Research Panel to support COVID-19 epidemiological studies. Overall, COVID-19 triggered the demand for sequencing platforms and panels for research purposes consequently boosting the market growth.